Efficacy of the escalating dose of naftopidil for patients with benign prostatic enlargement complicated by overactive bladder
Not Applicable
- Conditions
- Benign prostatic hyperplasia
- Registration Number
- JPRN-UMIN000020031
- Lead Sponsor
- Department of Urology Nagoya University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
Patients were excluded if they received oral treatment with alpha1-blockers, anticholinergic agents, 5-alpha reductase inhibitor (5-ARI), antidepressants, anti-anxiety agents, or sex hormonal agents; had neurogenic bladder dysfunction, bladder calculi, or active urinary tract infection; and had severe cardiac disease, renal dysfunction (serum creatinine level > 2 mg/dL), and hepatic dysfunction (aspartate and alanine aminotransferase concentrations more than twice the normal values).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method